Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 14,656 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 14,656 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $12.29, for a total value of $180,122.24. Following the transaction, the chief executive officer now owns 261,361 shares of the company's stock, valued at approximately $3,212,126.69. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, March 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00.
• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00.

Centessa Pharmaceuticals Stock Performance

Shares of Centessa Pharmaceuticals stock traded up $0.18 on Friday, reaching $13.79. 480,936 shares of the company were exchanged, compared to its average volume of 607,292. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of -9.01 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company's 50-day moving average is $14.42 and its two-hundred day moving average is $15.87.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. State Street Corp acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $777,000. Geode Capital Management LLC increased its position in Centessa Pharmaceuticals by 68.7% in the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock valued at $905,000 after acquiring an additional 23,058 shares during the period. Franklin Resources Inc. increased its position in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after acquiring an additional 1,145,823 shares during the period. Lord Abbett & CO. LLC bought a new stake in Centessa Pharmaceuticals during the 3rd quarter valued at $4,305,000. Finally, JPMorgan Chase & Co. boosted its position in Centessa Pharmaceuticals by 1,969.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock worth $2,173,000 after acquiring an additional 129,335 shares during the period. 82.01% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on CNTA shares. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating for the company. Finally, Morgan Stanley reissued an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of "Buy" and an average price target of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.